Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 26,400 shares, a drop of 22.8% from the September 30th total of 34,200 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily trading volume, of 2,600,000 shares, the short-interest ratio is presently 0.0 days.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a report on Wednesday, October 9th. They issued a “sell” rating on the stock.
View Our Latest Research Report on Galmed Pharmaceuticals
Galmed Pharmaceuticals Price Performance
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Buy P&G Now, Before It Sets A New All-Time High
- 3 ETFs With Low Fees and Market-Beating Returns
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Inflation Threats Make Yield Curve ETFs a Top Trade
- How to Invest in Small Cap StocksĀ
- Double-Digit Gains Ahead? Top 2 Stocks Positioned to Outperform
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.